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AsymptomatictermneonatesborntomotherswhoareGroupBStreptococcus(GBS)unknownorGBSpositivebut“inadequately”
treated prior to delivery do not require invasive laboratory evaluation. We conducted a retrospective cohort study of mother/baby
dyads born from January 1, 2005 until September 30, 2007 at the Medical College of Georgia. Their current protocol is to
obtain a Complete Blood Count with Diﬀerential (CBC with D), Blood Culture (BC), and C-reactive protein (CRP) after birth.
Mother/baby dyads (n = 242) that met inclusion criteria were reviewed. Of these 242 babies 25 (10%) were started on antibiotics
after the initial lab values were known. None of the blood cultures were positive and the CRP’s were normal. The 2002 GBS
guidelines call for laboratory evaluation of “at-risk” neonates, but the workup of these babies is not only costly, it does not provide
any advantage over old fashioned clinical observation for the evaluation and treatment of early onset GBS sepsis.
1.Introduction
Group B Streptococcus (GBS) is a gram-positive cocci that
may be found in the gastrointestinal tract, respiratory tract,
urinary tract, and genital tract [1]. It is one of the most
common causes of early onset neonatal sepsis, which occurs
within the ﬁrst 6 days of life. Approximately 30% of women
have asymptomatic GBS colonization at some point during
theirpregnancy,andabout20%remaincolonizedatthetime
ofbirth[1].GBShasnineserotypesthathavebeenidentiﬁed,
which are diﬀerentiated by the polysaccharide capsule of the
organism. Types I, II, and III are most commonly associated
with neonatal sepsis, with type III being highly associated
with central nervous system involvement [2].
Asymptomatic term neonates born to mothers who
are GBS unknown or GBS positive but “inadequately”
treated prior to delivery do not require invasive laboratory
evaluation [1, 3]. This evaluation may include a Complete
Blood Count with Diﬀerential (CBC with D), a Blood
Culture (BC), and a C-reactive protein (CRP). The Center
for Disease Control (CDC) 2002 GBS guidelines call for a
laboratory evaluation of “at risk” neonates, but they do not
provide data to the usefulness of this practice [4].
Laboratory evaluation of these babies is low yield, costly,
and disrupts mother baby bonding soon after birth. These
babies can be appropriately managed with careful clinical
observation for signs and symptoms of sepsis. Our primary
outcome was to determine the number of cases of sepsis that
were diagnosed based on these screening practices.
2.MaterialsandMethods
We conducted a retrospective cohort study of mother/baby
dyads born and cared for in the newborn nursery at the
Medical College of Georgia (MCG) in Augusta,Georgia. Our
study was from January 1, 2005 until September 30, 2007.
During this time period 5,342 babies were born. Inclusion
criteria consisted of babies born at term (>37 weeks com-
pleted gestation), mother’s GBS status unknown or positive2 Infectious Diseases in Obstetrics and Gynecology
at the time of delivery, no antibiotics or antibiotics less than
4h o u r sp r i o rt od e l i v e r y ,a n dal a b o r a t o r ye v a l u a t i o nu p o n
admission to the newborn nursery. There were no exclusion
criteria.
The current protocol in the newborn nursery is to obtain
a Complete Blood Count with a Diﬀerential (CBC with
D), a Blood Culture (BC), and a C-reactive protein (CRP)
immediatelyafterbirth.Thenbasedontheresultsoftheselab
tests and the discretion of the attending the decision about
whether to start antibiotics is made.
The study was approved by the Institution Review Board
at the hospital.
3. Results
During the study period there were 242 mother/baby dyads
that met the inclusion criteria. Of these 242 babies only
25 (10%) were started on antibiotics. The decision to start
antibiotics was made by an attending general pediatrician
based on the initial lab values. The antibiotic regimen was
Ampicillin 100mg/kg/dose every 12 hours and Gentamicin
4mg/kg/dose every 24 hours. Antibiotic therapy was discon-
tinued after 48 hours on 23 out of the 25 babies that were
started on antibiotics, and the other 2 babies received 7 days
of antibiotics for signs of clinical sepsis. Both of these babies
werein the GBSpositive No antibiotics group, and both were
discharged in good health after completing their antibiotic
course. None of the 242 babies had a positive blood culture
and the C-reactive protein levels were normal.
4. Discussion
In this era of intrapartum prophylaxis for early onset GBS
disease, we have seen a decline in the rate of early onset GBS
disease from 0.6 per 1000 in live births in 2000 to 0.39 per
1000 live births in 2006 [5, 6]. The 2002 CDC guidelines
have been eﬀective at reducing the incidence of early onset
GBS sepsis. However, the guidelines do not address or give
support to the “limited evaluation” of asymptomatic babies.
Saﬁer et al. estimated that based on the current rate of
GBS disease it would take about 10,000 blood cultures to
identify 1 case of GBS sepsis [7]. Ottolini et al. found similar
ﬁndings, as they did not have a positive blood culture in
1665 “at risk” term newborns [3]. In our institution, if a
baby is delivered and the mother’s GBS status is unknown
or a maternal transfer without her complete medical record,
then the obstetricians risk stratify the mother per the 2002
CDC guidelines [4]. If she does not meet the criteria for
intrapartum prophylaxis, then she does not receive antibi-
otics. The problem arises in that the pediatricians treat an
unknown GBS status as potential positive, and even though
the mother appropriately does not receive antibiotics, the
baby is subjected to a laboratory evaluation. The disconnect
between the obstetricians and the pediatrician causes serious
questions for these mothers who have just given birth. Many
times the pediatricians tell the mother that since the GBS
status was not known and she did not receive antibiotics that
her baby will require an invasive laboratory evaluation. The
Table 1: Number of babies treated based on mother’s GBS status








antibiotics 36 8 0
GBS unknown 1
dose antibiotics 25 1 0
GBS positive No
antibiotics 51 5 0
GBS positive 1 dose
Antibiotics 130 11 0
Totals 242 25 0
Table 2: Lab results for babies not treated with antibiotics after
delivery and babies treated with antibiotics after delivery.
No antibiotics Yes antibiotics
n = 217 n = 25
White blood cell count 19.2 20.9
I:T ratio 0.09 0.30
C-reactive protein 0.28 0.68
mother then questions her obstetrician as to why she was
not given antibiotics. This has led to obstetricians to give
antibiotics to mothers who do not meet criteria based on
the 2002 CDC guidelines in order to keep the pediatricians
from subjecting asymptomatic neonates from this invasive
evaluation.Anotherfactoristhe4-hourwindowrequiredfor
appropriate treatment of intrapartum antibiotics from the
timetheﬁrstdoesofantibioticsisgivenuntilthedelivery[4].
More than half of our babies were evaluated solely based on
the fact that the delivery occurred prior to this 4-hour cutoﬀ.
There have been several studies that have questioned this 4-
hour window [8, 9]. Bloom et al. showed that bactericidal
concentrations of ampicillin could be achieved within 5
minutes after infusion in both maternal and umbilical cord
sera [10]. The New Zealand GBS Consensus Working Party
that “well appearing babies born >35 weeks gestation to
women with GBS risk factors who have received either
no or inadequate (<4 hours) chemoprophylaxis should be
observed closely in hospital for at least 24 hours” [11].
5. Conclusions
In conclusion, we feel that clinical observation, rather than
an indepth laboratory workup is suﬃcient for the evaluation
of asymptomatic, GBS “at-risk” neonates. The results of our
study support the conclusion that subjecting asymptomatic
neonates to multiple blood draws and invasive laboratory
procedures is low yield. Furthermore, we feel it is costly and
disrupts maternal/child bonding. We recommend, rather,
that the clinician should implement serial examinations
for the observation of sepsis. Laboratory exams should be
initially withheld, though implemented if clinical suspicion
warrants. We feel this approach is more cost eﬀective andInfectious Diseases in Obstetrics and Gynecology 3
less invasive while providing the same level of care. Further
studies are needed to provide data to further stratify the need
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